Status:
UNKNOWN
Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Clopidogrel low response is associated with a significantly higher risk for ischemic complications after percutaneous coronary intervention. Ticagrelor and prasugrel are more potent platelet inhibitor...
Eligibility Criteria
Inclusion
- successful PCI
- 600 mg clopidogrel pretreatment
- clopidogrel low response assessed with electrode aggregometry (\>= 486 AU\*min)
- written informed consent
Exclusion
- Contraindications or allergies against study drugs
- Anemia
- Any surgery \< 6 weeks
- Increased bleeding risk
- Oral anticoagulation
- platelet count \< 100.000/µl
- Prior history of stroke or pathologic intracranial findings
- GPIIb/IIIa antagonists \< 10 days or periprocedural
- Age \> 80 years, \< 18 years
- Body weight \< 60 kg
- Cardiogenic shock
- Increased risk of bradycardia
- Moderate liver disease
- Kidney dialysis
- Intake of CYP 3A4 inhibitors
- Pregnancy or lactation
- Missing pregnancy test for women capable of bearing children
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2014
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01456364
Start Date
September 1 2011
End Date
May 1 2014
Last Update
November 1 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Deutsches Herzzentrum
München, Bavaria, Germany, 80636
2
Klinikum der Ludwig-Maximilians-Universität München
München, Bavaria, Germany, 81377
3
Heart Center Balatonfüred, Dept. of Cardiology
Balatonfüred, Hungary, 8230